Cost-effectiveness of two versus three or more doses of intermittent preventive treatment for malaria during pregnancy in sub-Saharan Africa: a modelling study of meta-analysis and cost data.
Identifieur interne : 000905 ( PubMed/Curation ); précédent : 000904; suivant : 000906Cost-effectiveness of two versus three or more doses of intermittent preventive treatment for malaria during pregnancy in sub-Saharan Africa: a modelling study of meta-analysis and cost data.
Auteurs : Silke Fernandes [Royaume-Uni] ; Elisa Sicuri [Espagne] ; Kassoum Kayentao [Mali] ; Anne Maria Van Eijk [Royaume-Uni] ; Jenny Hill [Royaume-Uni] ; Jayne Webster [Royaume-Uni] ; Vincent Were [Kenya] ; James Akazili [Ghana] ; Mwayi Madanitsa [Malawi] ; Feiko O. Ter Kuile [Kenya] ; Kara Hanson [Royaume-Uni]Source :
- The Lancet. Global health [ 2214-109X ] ; 2015.
Descripteurs français
- KwdFr :
- Afrique subsaharienne, Analyse coût-bénéfice, Années de vie ajustées sur la qualité, Antipaludiques (administration et posologie), Antipaludiques (usage thérapeutique), Antipaludiques (économie), Anémie (), Association médicamenteuse, Complications parasitaires de la grossesse (), Complications parasitaires de la grossesse (économie), Femelle, Grossesse, Humains, Nourrisson à faible poids de naissance, Paludisme (), Paludisme (économie), Pyriméthamine (administration et posologie), Pyriméthamine (usage thérapeutique), Pyriméthamine (économie), Sulfadoxine (administration et posologie), Sulfadoxine (usage thérapeutique), Sulfadoxine (économie).
- MESH :
- administration et posologie : Antipaludiques, Pyriméthamine, Sulfadoxine.
- usage thérapeutique : Antipaludiques, Pyriméthamine, Sulfadoxine.
- économie : Antipaludiques, Complications parasitaires de la grossesse, Paludisme, Pyriméthamine, Sulfadoxine.
- Afrique subsaharienne, Analyse coût-bénéfice, Années de vie ajustées sur la qualité, Anémie, Association médicamenteuse, Complications parasitaires de la grossesse, Femelle, Grossesse, Humains, Nourrisson à faible poids de naissance, Paludisme.
English descriptors
- KwdEn :
- Africa South of the Sahara, Anemia (prevention & control), Antimalarials (administration & dosage), Antimalarials (economics), Antimalarials (therapeutic use), Cost-Benefit Analysis, Drug Combinations, Female, Humans, Infant, Low Birth Weight, Malaria (complications), Malaria (economics), Malaria (prevention & control), Pregnancy, Pregnancy Complications, Parasitic (economics), Pregnancy Complications, Parasitic (prevention & control), Pyrimethamine (administration & dosage), Pyrimethamine (economics), Pyrimethamine (therapeutic use), Quality-Adjusted Life Years, Sulfadoxine (administration & dosage), Sulfadoxine (economics), Sulfadoxine (therapeutic use).
- MESH :
- chemical , administration & dosage : Antimalarials, Pyrimethamine, Sulfadoxine.
- chemical , economics : Antimalarials, Pyrimethamine, Sulfadoxine.
- chemical , therapeutic use : Antimalarials, Pyrimethamine, Sulfadoxine.
- geographic : Africa South of the Sahara, Drug Combinations.
- complications : Malaria.
- economics : Malaria, Pregnancy Complications, Parasitic.
- prevention & control : Anemia, Malaria, Pregnancy Complications, Parasitic.
- Cost-Benefit Analysis, Female, Humans, Infant, Low Birth Weight, Pregnancy, Quality-Adjusted Life Years.
Abstract
In 2012, WHO changed its recommendation for intermittent preventive treatment of malaria during pregnancy (IPTp) from two doses to monthly doses of sulfadoxine-pyrimethamine during the second and third trimesters, but noted the importance of a cost-effectiveness analysis to lend support to the decision of policy makers. We therefore estimated the incremental cost-effectiveness of IPTp with three or more (IPTp-SP3+) versus two doses of sulfadoxine-pyrimethamine (IPTp-SP2).
DOI: 10.1016/S2214-109X(14)70385-7
PubMed: 25701992
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000906
Links to Exploration step
pubmed:25701992Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cost-effectiveness of two versus three or more doses of intermittent preventive treatment for malaria during pregnancy in sub-Saharan Africa: a modelling study of meta-analysis and cost data.</title><author><name sortKey="Fernandes, Silke" sort="Fernandes, Silke" uniqKey="Fernandes S" first="Silke" last="Fernandes">Silke Fernandes</name><affiliation wicri:level="1"><nlm:affiliation>London School of Hygiene & Tropical Medicine, Keppel Street, London, UK. Electronic address: silke.fernandes@lshtm.ac.uk.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>London School of Hygiene & Tropical Medicine, Keppel Street, London</wicri:regionArea></affiliation></author><author><name sortKey="Sicuri, Elisa" sort="Sicuri, Elisa" uniqKey="Sicuri E" first="Elisa" last="Sicuri">Elisa Sicuri</name><affiliation wicri:level="1"><nlm:affiliation>ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic-Universitat de Barcelona, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Kayentao, Kassoum" sort="Kayentao, Kassoum" uniqKey="Kayentao K" first="Kassoum" last="Kayentao">Kassoum Kayentao</name><affiliation wicri:level="1"><nlm:affiliation>Liverpool School of Tropical Medicine, Liverpool, UK; Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.</nlm:affiliation><country xml:lang="fr">Mali</country><wicri:regionArea>Liverpool School of Tropical Medicine, Liverpool, UK; Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, University of Sciences, Techniques and Technologies of Bamako, Bamako</wicri:regionArea></affiliation></author><author><name sortKey="Van Eijk, Anne Maria" sort="Van Eijk, Anne Maria" uniqKey="Van Eijk A" first="Anne Maria" last="Van Eijk">Anne Maria Van Eijk</name><affiliation wicri:level="1"><nlm:affiliation>Liverpool School of Tropical Medicine, Liverpool, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Liverpool School of Tropical Medicine, Liverpool</wicri:regionArea></affiliation></author><author><name sortKey="Hill, Jenny" sort="Hill, Jenny" uniqKey="Hill J" first="Jenny" last="Hill">Jenny Hill</name><affiliation wicri:level="1"><nlm:affiliation>Liverpool School of Tropical Medicine, Liverpool, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Liverpool School of Tropical Medicine, Liverpool</wicri:regionArea></affiliation></author><author><name sortKey="Webster, Jayne" sort="Webster, Jayne" uniqKey="Webster J" first="Jayne" last="Webster">Jayne Webster</name><affiliation wicri:level="1"><nlm:affiliation>London School of Hygiene & Tropical Medicine, Keppel Street, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>London School of Hygiene & Tropical Medicine, Keppel Street, London</wicri:regionArea></affiliation></author><author><name sortKey="Were, Vincent" sort="Were, Vincent" uniqKey="Were V" first="Vincent" last="Were">Vincent Were</name><affiliation wicri:level="1"><nlm:affiliation>KEMRI/CDC Research and Public Health Collaboration, Kisumu, Kenya.</nlm:affiliation><country xml:lang="fr">Kenya</country><wicri:regionArea>KEMRI/CDC Research and Public Health Collaboration, Kisumu</wicri:regionArea></affiliation></author><author><name sortKey="Akazili, James" sort="Akazili, James" uniqKey="Akazili J" first="James" last="Akazili">James Akazili</name><affiliation wicri:level="1"><nlm:affiliation>Navrongo Health Research Centre, Navrongo, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Navrongo Health Research Centre, Navrongo</wicri:regionArea></affiliation></author><author><name sortKey="Madanitsa, Mwayi" sort="Madanitsa, Mwayi" uniqKey="Madanitsa M" first="Mwayi" last="Madanitsa">Mwayi Madanitsa</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine, University of Malawi, Blantyre, Malawi.</nlm:affiliation><country xml:lang="fr">Malawi</country><wicri:regionArea>College of Medicine, University of Malawi, Blantyre</wicri:regionArea></affiliation></author><author><name sortKey="Ter Kuile, Feiko O" sort="Ter Kuile, Feiko O" uniqKey="Ter Kuile F" first="Feiko O" last="Ter Kuile">Feiko O. Ter Kuile</name><affiliation wicri:level="1"><nlm:affiliation>Liverpool School of Tropical Medicine, Liverpool, UK; KEMRI/CDC Research and Public Health Collaboration, Kisumu, Kenya.</nlm:affiliation><country xml:lang="fr">Kenya</country><wicri:regionArea>Liverpool School of Tropical Medicine, Liverpool, UK; KEMRI/CDC Research and Public Health Collaboration, Kisumu</wicri:regionArea></affiliation></author><author><name sortKey="Hanson, Kara" sort="Hanson, Kara" uniqKey="Hanson K" first="Kara" last="Hanson">Kara Hanson</name><affiliation wicri:level="1"><nlm:affiliation>London School of Hygiene & Tropical Medicine, Keppel Street, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>London School of Hygiene & Tropical Medicine, Keppel Street, London</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25701992</idno><idno type="pmid">25701992</idno><idno type="doi">10.1016/S2214-109X(14)70385-7</idno><idno type="wicri:Area/PubMed/Corpus">000906</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000906</idno><idno type="wicri:Area/PubMed/Curation">000905</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000905</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cost-effectiveness of two versus three or more doses of intermittent preventive treatment for malaria during pregnancy in sub-Saharan Africa: a modelling study of meta-analysis and cost data.</title><author><name sortKey="Fernandes, Silke" sort="Fernandes, Silke" uniqKey="Fernandes S" first="Silke" last="Fernandes">Silke Fernandes</name><affiliation wicri:level="1"><nlm:affiliation>London School of Hygiene & Tropical Medicine, Keppel Street, London, UK. Electronic address: silke.fernandes@lshtm.ac.uk.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>London School of Hygiene & Tropical Medicine, Keppel Street, London</wicri:regionArea></affiliation></author><author><name sortKey="Sicuri, Elisa" sort="Sicuri, Elisa" uniqKey="Sicuri E" first="Elisa" last="Sicuri">Elisa Sicuri</name><affiliation wicri:level="1"><nlm:affiliation>ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic-Universitat de Barcelona, Barcelona</wicri:regionArea></affiliation></author><author><name sortKey="Kayentao, Kassoum" sort="Kayentao, Kassoum" uniqKey="Kayentao K" first="Kassoum" last="Kayentao">Kassoum Kayentao</name><affiliation wicri:level="1"><nlm:affiliation>Liverpool School of Tropical Medicine, Liverpool, UK; Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.</nlm:affiliation><country xml:lang="fr">Mali</country><wicri:regionArea>Liverpool School of Tropical Medicine, Liverpool, UK; Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, University of Sciences, Techniques and Technologies of Bamako, Bamako</wicri:regionArea></affiliation></author><author><name sortKey="Van Eijk, Anne Maria" sort="Van Eijk, Anne Maria" uniqKey="Van Eijk A" first="Anne Maria" last="Van Eijk">Anne Maria Van Eijk</name><affiliation wicri:level="1"><nlm:affiliation>Liverpool School of Tropical Medicine, Liverpool, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Liverpool School of Tropical Medicine, Liverpool</wicri:regionArea></affiliation></author><author><name sortKey="Hill, Jenny" sort="Hill, Jenny" uniqKey="Hill J" first="Jenny" last="Hill">Jenny Hill</name><affiliation wicri:level="1"><nlm:affiliation>Liverpool School of Tropical Medicine, Liverpool, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Liverpool School of Tropical Medicine, Liverpool</wicri:regionArea></affiliation></author><author><name sortKey="Webster, Jayne" sort="Webster, Jayne" uniqKey="Webster J" first="Jayne" last="Webster">Jayne Webster</name><affiliation wicri:level="1"><nlm:affiliation>London School of Hygiene & Tropical Medicine, Keppel Street, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>London School of Hygiene & Tropical Medicine, Keppel Street, London</wicri:regionArea></affiliation></author><author><name sortKey="Were, Vincent" sort="Were, Vincent" uniqKey="Were V" first="Vincent" last="Were">Vincent Were</name><affiliation wicri:level="1"><nlm:affiliation>KEMRI/CDC Research and Public Health Collaboration, Kisumu, Kenya.</nlm:affiliation><country xml:lang="fr">Kenya</country><wicri:regionArea>KEMRI/CDC Research and Public Health Collaboration, Kisumu</wicri:regionArea></affiliation></author><author><name sortKey="Akazili, James" sort="Akazili, James" uniqKey="Akazili J" first="James" last="Akazili">James Akazili</name><affiliation wicri:level="1"><nlm:affiliation>Navrongo Health Research Centre, Navrongo, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Navrongo Health Research Centre, Navrongo</wicri:regionArea></affiliation></author><author><name sortKey="Madanitsa, Mwayi" sort="Madanitsa, Mwayi" uniqKey="Madanitsa M" first="Mwayi" last="Madanitsa">Mwayi Madanitsa</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine, University of Malawi, Blantyre, Malawi.</nlm:affiliation><country xml:lang="fr">Malawi</country><wicri:regionArea>College of Medicine, University of Malawi, Blantyre</wicri:regionArea></affiliation></author><author><name sortKey="Ter Kuile, Feiko O" sort="Ter Kuile, Feiko O" uniqKey="Ter Kuile F" first="Feiko O" last="Ter Kuile">Feiko O. Ter Kuile</name><affiliation wicri:level="1"><nlm:affiliation>Liverpool School of Tropical Medicine, Liverpool, UK; KEMRI/CDC Research and Public Health Collaboration, Kisumu, Kenya.</nlm:affiliation><country xml:lang="fr">Kenya</country><wicri:regionArea>Liverpool School of Tropical Medicine, Liverpool, UK; KEMRI/CDC Research and Public Health Collaboration, Kisumu</wicri:regionArea></affiliation></author><author><name sortKey="Hanson, Kara" sort="Hanson, Kara" uniqKey="Hanson K" first="Kara" last="Hanson">Kara Hanson</name><affiliation wicri:level="1"><nlm:affiliation>London School of Hygiene & Tropical Medicine, Keppel Street, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>London School of Hygiene & Tropical Medicine, Keppel Street, London</wicri:regionArea></affiliation></author></analytic><series><title level="j">The Lancet. Global health</title><idno type="eISSN">2214-109X</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Africa South of the Sahara</term><term>Anemia (prevention & control)</term><term>Antimalarials (administration & dosage)</term><term>Antimalarials (economics)</term><term>Antimalarials (therapeutic use)</term><term>Cost-Benefit Analysis</term><term>Drug Combinations</term><term>Female</term><term>Humans</term><term>Infant, Low Birth Weight</term><term>Malaria (complications)</term><term>Malaria (economics)</term><term>Malaria (prevention & control)</term><term>Pregnancy</term><term>Pregnancy Complications, Parasitic (economics)</term><term>Pregnancy Complications, Parasitic (prevention & control)</term><term>Pyrimethamine (administration & dosage)</term><term>Pyrimethamine (economics)</term><term>Pyrimethamine (therapeutic use)</term><term>Quality-Adjusted Life Years</term><term>Sulfadoxine (administration & dosage)</term><term>Sulfadoxine (economics)</term><term>Sulfadoxine (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Afrique subsaharienne</term><term>Analyse coût-bénéfice</term><term>Années de vie ajustées sur la qualité</term><term>Antipaludiques (administration et posologie)</term><term>Antipaludiques (usage thérapeutique)</term><term>Antipaludiques (économie)</term><term>Anémie ()</term><term>Association médicamenteuse</term><term>Complications parasitaires de la grossesse ()</term><term>Complications parasitaires de la grossesse (économie)</term><term>Femelle</term><term>Grossesse</term><term>Humains</term><term>Nourrisson à faible poids de naissance</term><term>Paludisme ()</term><term>Paludisme (économie)</term><term>Pyriméthamine (administration et posologie)</term><term>Pyriméthamine (usage thérapeutique)</term><term>Pyriméthamine (économie)</term><term>Sulfadoxine (administration et posologie)</term><term>Sulfadoxine (usage thérapeutique)</term><term>Sulfadoxine (économie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antimalarials</term><term>Pyrimethamine</term><term>Sulfadoxine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Antimalarials</term><term>Pyrimethamine</term><term>Sulfadoxine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antimalarials</term><term>Pyrimethamine</term><term>Sulfadoxine</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Africa South of the Sahara</term><term>Drug Combinations</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antipaludiques</term><term>Pyriméthamine</term><term>Sulfadoxine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Malaria</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Malaria</term><term>Pregnancy Complications, Parasitic</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Anemia</term><term>Malaria</term><term>Pregnancy Complications, Parasitic</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antipaludiques</term><term>Pyriméthamine</term><term>Sulfadoxine</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Antipaludiques</term><term>Complications parasitaires de la grossesse</term><term>Paludisme</term><term>Pyriméthamine</term><term>Sulfadoxine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cost-Benefit Analysis</term><term>Female</term><term>Humans</term><term>Infant, Low Birth Weight</term><term>Pregnancy</term><term>Quality-Adjusted Life Years</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Afrique subsaharienne</term><term>Analyse coût-bénéfice</term><term>Années de vie ajustées sur la qualité</term><term>Anémie</term><term>Association médicamenteuse</term><term>Complications parasitaires de la grossesse</term><term>Femelle</term><term>Grossesse</term><term>Humains</term><term>Nourrisson à faible poids de naissance</term><term>Paludisme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In 2012, WHO changed its recommendation for intermittent preventive treatment of malaria during pregnancy (IPTp) from two doses to monthly doses of sulfadoxine-pyrimethamine during the second and third trimesters, but noted the importance of a cost-effectiveness analysis to lend support to the decision of policy makers. We therefore estimated the incremental cost-effectiveness of IPTp with three or more (IPTp-SP3+) versus two doses of sulfadoxine-pyrimethamine (IPTp-SP2).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25701992</PMID><DateCreated><Year>2015</Year><Month>02</Month><Day>23</Day></DateCreated><DateCompleted><Year>2015</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2015</Year><Month>02</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2214-109X</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Lancet. Global health</Title><ISOAbbreviation>Lancet Glob Health</ISOAbbreviation></Journal><ArticleTitle>Cost-effectiveness of two versus three or more doses of intermittent preventive treatment for malaria during pregnancy in sub-Saharan Africa: a modelling study of meta-analysis and cost data.</ArticleTitle><Pagination><MedlinePgn>e143-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2214-109X(14)70385-7</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2214-109X(14)70385-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In 2012, WHO changed its recommendation for intermittent preventive treatment of malaria during pregnancy (IPTp) from two doses to monthly doses of sulfadoxine-pyrimethamine during the second and third trimesters, but noted the importance of a cost-effectiveness analysis to lend support to the decision of policy makers. We therefore estimated the incremental cost-effectiveness of IPTp with three or more (IPTp-SP3+) versus two doses of sulfadoxine-pyrimethamine (IPTp-SP2).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">For this analysis, we used data from a 2013 meta-analysis of seven studies in sub-Saharan Africa. We developed a decision tree model with a lifetime horizon. We analysed the base case from a societal perspective. We did deterministic and probabilistic sensitivity analyses with appropriate parameter ranges and distributions for settings with low, moderate, and high background risk of low birthweight, and did a separate analysis for HIV-negative women. Parameters in the model were obtained for all countries included in the original meta-analysis. We did simulations in hypothetical cohorts of 1000 pregnant women receiving either IPTp-SP3+ or IPTp-SP2. We calculated disability-adjusted life-years (DALYs) for low birthweight, severe to moderate anaemia, and clinical malaria. We calculated cost estimates from data obtained in observational studies, exit surveys, and from public procurement databases. We give financial and economic costs in constant 2012 US$. The main outcome measure was the incremental cost per DALY averted.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">The delivery of IPTp-SP3+ to 1000 pregnant women averted 113·4 DALYs at an incremental cost of $825·67 producing an incremental cost-effectiveness ratio (ICER) of $7·28 per DALY averted. The results remained robust in the deterministic sensitivity analysis. In the probabilistic sensitivity analyses, the ICER was $7·7 per DALY averted for moderate risk of low birthweight, $19·4 per DALY averted for low risk, and $4·0 per DALY averted for high risk. The ICER for HIV-negative women was $6·2 per DALY averted.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our findings lend strong support to the WHO guidelines that recommend a monthly dose of IPTp-SP from the second trimester onwards.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Malaria in Pregnancy Consortium and the Bill & Melinda Gates Foundation.</AbstractText><CopyrightInformation>Copyright © 2015 Fernandes et al. Open Access article distributed under the terms of CC BY-NC-SA. Published by .. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fernandes</LastName><ForeName>Silke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>London School of Hygiene & Tropical Medicine, Keppel Street, London, UK. Electronic address: silke.fernandes@lshtm.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sicuri</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kayentao</LastName><ForeName>Kassoum</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Liverpool School of Tropical Medicine, Liverpool, UK; Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Eijk</LastName><ForeName>Anne Maria</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Liverpool School of Tropical Medicine, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Jenny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Liverpool School of Tropical Medicine, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Webster</LastName><ForeName>Jayne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>London School of Hygiene & Tropical Medicine, Keppel Street, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Were</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>KEMRI/CDC Research and Public Health Collaboration, Kisumu, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akazili</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Navrongo Health Research Centre, Navrongo, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madanitsa</LastName><ForeName>Mwayi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>College of Medicine, University of Malawi, Blantyre, Malawi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>ter Kuile</LastName><ForeName>Feiko O</ForeName><Initials>FO</Initials><AffiliationInfo><Affiliation>Liverpool School of Tropical Medicine, Liverpool, UK; KEMRI/CDC Research and Public Health Collaboration, Kisumu, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanson</LastName><ForeName>Kara</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>London School of Hygiene & Tropical Medicine, Keppel Street, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Glob Health</MedlineTA><NlmUniqueID>101613665</NlmUniqueID><ISSNLinking>2214-109X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>37338-39-9</RegistryNumber><NameOfSubstance UI="C001205">fanasil, pyrimethamine drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>88463U4SM5</RegistryNumber><NameOfSubstance UI="D013413">Sulfadoxine</NameOfSubstance></Chemical><Chemical><RegistryNumber>Z3614QOX8W</RegistryNumber><NameOfSubstance UI="D011739">Pyrimethamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Glob Health. 2015 Mar;3(3):e116-7</RefSource><PMID Version="1">25701984</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017954" MajorTopicYN="N" Type="Geographic">Africa South of the Sahara</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000740" MajorTopicYN="N">Anemia</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="Y">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007230" MajorTopicYN="N">Infant, Low Birth Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008288" MajorTopicYN="N">Malaria</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015597" MajorTopicYN="N">Pregnancy Complications, Parasitic</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011739" MajorTopicYN="N">Pyrimethamine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="Y">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013413" MajorTopicYN="N">Sulfadoxine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25701992</ArticleId><ArticleId IdType="pii">S2214-109X(14)70385-7</ArticleId><ArticleId IdType="doi">10.1016/S2214-109X(14)70385-7</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000905 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000905 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:25701992
|texte= Cost-effectiveness of two versus three or more doses of intermittent preventive treatment for malaria during pregnancy in sub-Saharan Africa: a modelling study of meta-analysis and cost data.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:25701992" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |